Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
© 2023. The Author(s)..
BACKGROUND AND AIMS: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV).
METHODS: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19.
RESULTS: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04-0.67, p = 0.01).
CONCLUSION: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 68(2023), 6 vom: 03. Juni, Seite 2731-2737 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 24.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10620-022-07817-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352475978 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352475978 | ||
| 003 | DE-627 | ||
| 005 | 20231226053818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-022-07817-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352475978 | ||
| 035 | |a (NLM)36737575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mateos-Muñoz, Beatriz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 24.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND AND AIMS: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV) | ||
| 520 | |a METHODS: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19 | ||
| 520 | |a RESULTS: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04-0.67, p = 0.01) | ||
| 520 | |a CONCLUSION: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Entecavir | |
| 650 | 4 | |a Hepatitis B | |
| 650 | 4 | |a Tenofovir | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Buti, María |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez, Inmaculada Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a Conde, Marta Hernández |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal-Monterde, Vanesa |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Fontenla, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas, Rosa María |e verfasserin |4 aut | |
| 700 | 1 | |a García-Buey, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Badía, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Miquel, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Amador-Navarrete, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Tajes, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Merino, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Madejón, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a García-Retortillo, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Arenas, Juan Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Cabezas, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Santiago, Jesús Manuel González |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Rodríguez, Conrado |e verfasserin |4 aut | |
| 700 | 1 | |a Cordero, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Diago, Moisés |e verfasserin |4 aut | |
| 700 | 1 | |a Mancebo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pardo, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyas, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Jose Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Turnes, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Simón, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Marcos-Fosch, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Calleja, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Bañares, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Lens, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Samaniego, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gomez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Gea, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a de Santiago, Enrique Rodríguez |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Albillos, Agustin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 68(2023), 6 vom: 03. Juni, Seite 2731-2737 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2023 |g number:6 |g day:03 |g month:06 |g pages:2731-2737 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-022-07817-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2023 |e 6 |b 03 |c 06 |h 2731-2737 | ||